Entry

D10773                      Drug

Name

Atezolizumab (USAN/INN);
Atezolizumab (genetical recombination) (JAN);
Tecentriq (TN)

Product

TECENTRIQ (Genentech)

Formula

C6446H9902N1706O1998S42

Exact mass

144521.3941

Mol weight

144610.5555

Sequence

(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DSWIHWVRQA PGKGLEWVAW ISPYGGSTYY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARRH WPGGFDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYAST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLYHPATFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H145-H201, H221-L214, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'214, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'138-L'194)

Type

Peptide

Class

Antineoplastic
DG02938 Immune checkpoint inhibitor

Remark

Therapeutic category:

4291

ATC code:

L01FF05

Product:

D10773<JP/US>

Efficacy

Antineoplastic, Immune checkpoint inhibitor, Anti-PD-L1 antibody

Disease

Urothelial carcinoma [DS:H00022]
Urothelial carcinoma (PD-L1 expressed) [DS:H00022]
Non-small cell lung cancer [DS:H00014]
Breast cancer (PD-L1 expressed, HR negative, HER2 negative) [DS:H00031]
Small cell lung cancer [DS:H00013]
Hepatocellular carcinoma [DS:H00048]

Comment

Monoclonal antibody

Target

PDL1 (CD274) [HSA:29126] [KO:K06745]

Pathway

hsa04514

Cell adhesion molecules

hsa05235

PD-L1 expression and PD-1 checkpoint pathway in cancer

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF05 Atezolizumab
      D10773  Atezolizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Atezolizumab
    D10773  Atezolizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10773  Atezolizumab (USAN/INN); Atezolizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10773  Atezolizumab
Drug classes [BR:br08332]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10773  Atezolizumab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D10773  Atezolizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10773
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D10773
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D10773
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10773
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D10773

Other DBs

CAS:	1380723-44-3

PubChem:

312642102